Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)

NCT03664687 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

211

Enrollment

OTHER

Sponsor class

Conditions

Early-stage Breast Cancer

Interventions

DRUG: Zoledronate

Sponsor

Ottawa Hospital Research Institute